Stephen Squinto, PhD., named Vice Chairman of bioAffinity Technologies

PUBLISHED ON July 7, 2020

JULY 7, 2020 (San Antionio, TX) bioAffinity Technologies, a privately-held cancer diagnostics and therapeutics company, today announced that Stephen Squinto, Ph.D., has been named Vice Chairman of the Company’s Board of Directors, and David Elzi, Ph.D., has been appointed Vice President of Research in recognition of Dr. Elzi’s pivotal role in the Company’s scientific discoveries related to cancer therapeutics.

read more

bioAffinity Technologies Joins National Lung Cancer Roundtable

PUBLISHED ON October 11, 2019

OCTOBER 11, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced that it has been accepted as a member of the American Cancer Society’s National Lung Cancer Roundtable (NLCRT), a collaborative whose membership is focused on reducing both the incidence of lung cancer and mortality rates from the disease.

read more

bioAffinity Technologies Announces Members of its Scientific and Medical Advisory Board

PUBLISHED ON October 2, 2019

OCTOBER 2, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced the members of its Scientific and Medical Advisory (SMA) Board who will provide independent expert advice and counsel on the Company’s research and development of innovative cancer diagnostics, including CyPath® Lung, a non-invasive test for the early detection of lung cancer.

read more

bioAffinity Technologies was selected as one of San Antonio’s Top 2020 Innovators. In this video, you will see Maria Zannes, President and Chief Executive Officer, speak about what drives motivation, innovation and success and kick off San Antonio’s premier annual event celebrating the City’s healthcare and bioscience industry.